Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren dose-ranging study versus lisinopril in older adults with essential hypertension
2004-004255-18Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in essential hypertension (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in mean ambulatory 24-hour systolic blood pressure. Started Mar 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2004-004255-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004255-18.